Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Axikin Pharmaceuticals

Request full access

Small molecule therapeutics for respiratory and autoimmune diseases

San Diego, United StatesFounded 2008Biotech & Life Sciences

About Axikin Pharmaceuticals

Axikin Pharmaceuticals, Inc. was a clinical-stage biopharmaceutical company focused on developing and commercializing small molecule therapeutics. The company targeted severe respiratory, inflammatory, and autoimmune diseases such as asthma, chronic obstructive pulmonary disease (COPD), and allergic rhinitis.

Founded in 2008 by Kevin B. Bacon, Ph.D., Axikin was established as a spin-out from Actimis Pharmaceuticals. This occurred after Actimis' main program was acquired by Boehringer Ingelheim. The new entity retained key scientific staff and several preclinical programs from its predecessor, which originated from Bayer Yakuhin Ltd.'s respiratory research in Japan. The company was headquartered in San Diego, California. Dr. Bacon, who founded Actimis, served as Axikin's President and Chief Scientific Officer, while Dr. Peter C. M. McWilliams of Sanderling Ventures was the acting CEO.

The company's business model was centered on advancing its drug pipeline through preclinical and clinical stages, with the ultimate goal of partnering with larger pharmaceutical companies for late-stage development and commercialization. Axikin's lead candidate was AXP1275, an orally available allosteric modulator targeting the CCR3 chemokine receptor, which is known to be up-regulated in various allergic diseases. Axikin secured initial Series A funding of $3 million in January 2009, led by Sanderling Ventures and Mitsui & Co. Venture Partners, eventually raising a total of approximately $11.6 million to $12.5 million over several funding rounds. Despite its efforts, the company ceased operations around November 2017.

Source: Dealroom company data

Axikin Pharmaceuticals in the San Diego ecosystem

Live from Dealroom

The Axikin Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

2 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A2 investors entered at this stage

  • Sanderling Ventures
  • Mitsui Global Investment
Team profiled 6 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · San Diego HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Axikin Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Axikin Pharmaceuticals on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.